Our findings demonstrate that MSRA ameliorates valvular calcification and senescence by inhibiting TLR2/NF-κB pathway, highlighting MSRA as a promising target for treating age-associated CAVD. This evidence concerns the gene TLR2 and congenital bilateral aplasia of vas deferens from CFTR mutation.